Ramucirumab Plus FOLFOX as Front-Line Treatment in Advanced Gastric or Esophageal Cancer

July 8, 2014
Johanna Bendell, MD

Johanna Bendell, MD, Director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the results of a randomized, double-blind, multicenter phase II trial that examined FOLFOX with or without ramucirumab as front-line therapy for advanced gastric or esophageal adenocarcinoma.

Johanna Bendell, MD, Director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the results of a randomized, double-blind, multicenter phase II trial that examined FOLFOX with or without ramucirumab as front-line therapy for advanced gastric or esophageal adenocarcinoma.

Clinical Pearls:

  • Results of the study were negative in terms of benefit of progression-free survival combining ramucirumab and chemotherapy.
  • This study included patients with distal esophageal cancers, GEJ cancers and gastric cancers. Most of the benefit of the combination was seen in patients with GEJ and gastric cancers.
  • This may have clouded the overall results in terms of progression-free survival.
  • Researchers are working on figuring out if there is a reason why esophageal cancer patients did not seem to benefit from the combination.